OptiNose

OptiNose — Investor Presentation (June 2018)

20 slides from OptiNose's investor presentation, Jun 4, 2018

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.1 Building a Leading ENT / Allergy Specialty Company Corporate Presentation June 4, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Emerging Growth Company with Approved Products

    Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY XHANCE Represents a Significant Opportunity in Attractive ENT/Allergy Market • 3.5 Million CRS patients (1.2M with nasal polyps) being treated by 15,000 physicians • Limited competition anticipated from

  4. Slide 4: Recent Key Accomplishments

    Recent Key Accomplishments Retail Launch Aided Awareness April 2, 2018 87% within ENT / Allergy Specialty* Commercial 74% Lives Covered Total Trialists (61% Tier 3 Single Step or better)* 800 700 600 500 Encouraging 400 Submitted CS Physician Adoption 300 trial design to 200 in ENT / Allergy 100 FDA

  5. Slide 5: Successful Launches are Driven by Four Key Factors

    Our Research on Over 300 Products Suggests Successful Launches are Driven by Four Key Factors Attractive Market…with High Unmet Need Importantly Differentiated Product Awareness / Execution Market Access 5

  6. Slide 6: CRS is an Attractive Market…With High Unmet Need

    CRS is an Attractive Market…With High Unmet Need 30 Million High Burden US Adults suffer from CRS Disease persists for many years and up to 10 million • of them have nasal • Significant quality of life impact polyps (comparable to CHF, COPD, Angina) 9.75 Million CRS patients seek Recognized Unmet Ne

  7. Slide 7: $3.4B Market Opportunity Within Specialty

    $3.4B Market Opportunity Within Specialty TOTAL MARKET OPPORTUNITY OF >$9.5B (Nasal Polyps + CS Indications) SPECIALTY MARKET OPPORTUNITY INCREMENTAL PCP OPPORTUNITY KEY DRIVER 30 Million Chronic Rhinosinusitis Sufferers in US PREVALENCE (7 Million Have Had Surgery) OVERALL TREATED PATIENTS 9.75 Mil

  8. Slide 8: Perceived Differentiation of XHANCE on Key Choice Drivers

    Perceived Differentiation of XHANCE on Key Choice Drivers Translates into High Intention to Prescribe XHANCE is Perceived as Physician Stated Interest Differentiated on Key to Prescribe* Choice Drivers High Physician Interest in Prescribing is Reported After Presenting Product Profile (With Only Nas

  9. Slide 9: Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87%

    Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87% Awareness & Execution 87% . Digital and Non-Personal Awareness campaign 73% implemented 9/17/2017 65% . Clinical Nurse Educators deployed 11/18/2017 . Xhance Xperience program introduced in early March 28% . Approximately 80

  10. Slide 10: XHANCE has Good Early Launch Market Access

    XHANCE has Good Early Launch Market Access XHANCE Overall Access: April 2018 • Nationally, we believe 74% of commercial lives are in a plan where XHANCE is covered. 26% • We believe new drugs that launch at approval typically have 74% only 40% of commercial lives covered and 60% of commercial lives

  11. Slide 11: XHANCE National Market Access

    XHANCE National Market Access XHANCE Overall • We are focused on creating Access: April 2018 access for patients that minimizes hassle for prescribers and patients. 26% • XHANCE is on formulary for 65% 9% of commercial lives in a Tier 3 65% position requiring a previous trial of an INS or better. •

  12. Slide 12: XHANCE Xperience Program - Initiated in Market on March 5th

    XHANCE Xperience Program - Initiated in Market on March 5th XPERIENCE . Innovative launch program, planned for March through June, offering physicians and patients an opportunity to gain initial experience with XHANCE . Designed to facilitate accelerated trial and adoption, and to help address “prac

  13. Slide 13: XHANCE Launch Accelerated by Xperience

    XHANCE Launch Accelerated by Xperience (Week ending June 1, 2018) Cumulative Cumulative Units Dispensed Physician Trialists 9,850 1,792 10,000 1,800 As of June 1, 31% of called physicians have 1,600 prescribed XHANCE 8,000 1,400 1,200 6,000 1,000 800 4,000 600 2,000 400 200 0 0 Source: Cumulative ph

  14. Slide 14: Encouraging Feedback From Xperience Program Survey

    Encouraging Feedback From Xperience Program Survey Patient Responses Prior to Month 2 Refill (N=911) Patient Satisfaction 90% Experience Symptom 81% Improvement Prefer XHANCE 79% Recommend XHANCE 90% to a Friend Use without Difficulty 95% Note: in the same period that the 911 responses were received

  15. Slide 15: Strong Foundation for a Successful Launch

    Market Dynamics, Product Characteristics and Execution to Date Provide a Strong Foundation for a Successful Launch Indicator/Objective Assessment Attractive Market…with High Unmet Need >80% Current Patients Dissatisfied with Existing Treatment >80% of patients frustrated with lack of symptom relief

  16. Slide 16: Financial Review

    Financial Review Q1 2018 Revenues and Q2 and Full Year 2018 Average Selling Price (ASP) Perspectives • A large majority of Q1 revenue is • As planned, we expect the Xperience related to inventory shipped in late- program to be the primary source of March to support retail pharmacy demand for XHANCE

  17. Slide 17: Chronic Sinusitis Supplemental Indication (sNDA)

    Chronic Sinusitis Supplemental Indication (sNDA) CS study design Selection of CRO First patients submitted to and study expected to FDA, meeting locations enroll in 4Q 2018 requested Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation an

  18. Slide 18: 2018 Stands to be an Important Year

    2018 Stands to be an Important Year Achieve greater than 87% aided awareness in target ENT and allergist audience during retail launch Secure market access for XHANCE ≥65% of patients with commercial insurance plans at retail launch, expanding to 75% by year end Key Objectives Successfully launch XH

  19. Slide 19: Investor Relations

    Investor Relations – NASDAQ: OPTN At 31 March 2018: 1 Analyst Coverage – $210 million in cash – 37.9 million common shares o/s BMO: Gary Nachman – 8.2 million options & warrants o/s – Long-term debt: $75 million Jefferies: David Steinberg Optinose Investor Contact Jonathan Neely, VP, Investor Relati

  20. Slide 20: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company Corporate Presentation June 4, 2018

OptiNose — Investor Presentation (June 2018) on 6ix